Q2 EPS Estimates for TScan Therapeutics Cut by Wedbush
TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Analysts at Wedbush reduced their Q2 2025 EPS estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.26) per share for the quarter, down […]
TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Analysts at Wedbush reduced their Q2 2025 EPS estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.26) per share for the quarter, down […]
